Effects of Fenofibrate Treatment on Aortic Stiffness in Patients with Pure Hypertriglyceridemia

Abstract

Introduction: Hypertriglyceridemia is known as an independent risk factor for coronary artery disease (CAD). Fenofibrate that is used for the treatment of hypertriglyceridemia can prevent cardiovascular events in patients with CAD. However, there is little information regarding the vascular effects of fenofibrate on arterial wall stiffness in patients with hypertriglyceridemia and without CAD, diabetes mellitus (DT), and hypertension (HT). The objective of this study is to evaluate the effects of fenofibrate treatment on the arterial stiffness in the patients with pure hypertriglyceridemia. Patients and Methods: We included 37 patients with hypertriglyceridemia without CAD, HT, and DT in this study. We performed pre- and post-treament physical examination of the patients and took their blood samples. Patients were allocated fenofibrate for a duration of 168 ± 14 days for its administration. We assessed arterial stiffness by aortic pulse wave velocity (PWV) using a SphygmoCor device. Importantly, we estimated central arterial pressure waveform parameters by radial artery applanation tonometry and used augmentation index (AIx) as a measure of wave reflections. Results: Fenofibrate treatment resulted in significantly greater reductions in total cholesterol (201.3 ± 61.0 mg/dL vs. 270.0 ± 93.4 mg/dL), triglycerides (261.3 ± 234.3 mg/dL vs. 704.7 ± 338.7 mg/dL), and the C/H levels (5.3 ± 2.6 vs. 7.2 ± 1.9, respectively) as compared with the pretreatment levels (p< 0.001). There was a tendency of high-sensitivity C-reactive protein (hs-CRP) to decline after fenofibrate treatment as change in hs-CRP was significant (0.47 ± 0.41 mg/dL vs. 0.32 ± 0.31 mg/dL respectively, p< 0.01). AIx remained unchanged from the pretreatment levels (24.2% ± 12.4% vs. 22.0% ± 11.4%, respectively, p> 0.05). There was a significant reduction in PWV after fenofibrate treatment (11.3 ± 2.9 m/s vs. 9.2 ± 2.2 m/s, p= 0.001). Conclusion: Fenofibrate treatment appears to effectively improve the arterial wall stiffness in the patients with pure hypertriglyceridemia.

Keywords

• Hypertriglyceridemia
• aortic stiffness
• pulse wave velocity
• fenofibrate
• augmentation index

References

1. 1. Hennekens CH, Gaziano JM . Antioxidants and heart disease: epidemiology and clinical evidence. Clin Cardiol 1993;16:10-3.
2. 2. Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, et al. Triglycerides and the risk of coronary heart disease: 10 158 incident cases among 262 525 participants in 29 Western prospective studies. Circulation 2007;115:450-8.
3. 3. Balfour JA, McTavish D, Heel RC. Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia. Drugs 1990;40:260-90.
4. 4. Robins SJ, Collins D, Wittes JT, Papademetriou V, Deedwania PC, Schaefer EJ, et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: A randomized controlled trial. JAMA 2001;285:1585-91.
5. 5. Frost RJ, Otto C, Geiss HC, Schwandt P, Parhofer KG. Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia. Am J Cardiol 2001;87:44-8.
6. 6. Reiner Z. Are elevated serum triglycerides really a risk factor for coronary artery disease? Cardiology 2015;131:225-7.
7. 7. Acartürk E, Dörtlemez H. Efficacy and safety of fenofibrate in primary hyperlipidemic subjects. Turk Kardiyol Dern Ars 2000;28:121-5.
8. 8. Boutouyrie P, Isabelle A, Asmar R, Gatier I, Benetos A, Lacolley P, et al. Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: A longitudinal study. Hypertension 2002;39:10-5.

9. 9. Pannier B, Guerin AP, Marchais SJ, Safar ME, London GM. Stiffness of capacitative and conduit arteries: Prognostic significance for endstage renal disease patients. Hypertension 2005;45:592-6.
10. 10. Cruickshank K, Riste L, Anderson SG, Wright JS, Dunn G, Gosling RG. Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function? Circulation 2002;106:2085-90.
11. 11. Blacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME, London GM. Impact of aortic stiffness on survival in end-stage renal disease. Circulation 1999;99:2434-9.
12. 12. Mitchell GF, Wang N, Palmisano JN, Larson MG, Hamburg NM, Vita JA, et al. Hemodynamic correlates of blood pressure across the adult age spectrum: noninvasive evaluation in the Framingham Heart Study. Circulation 2010;122:1379-86.
13. 13. Boutouyrie P, Bruno RM. The clinical significance and application of vascular stiffness measurements. Am J Hypertens 2018;32:4-11.
14. 14. Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, et al. European network for non-invasive investigation of large arteries. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006;27:2588.
15. 15. O’Rourke MF, Gallagher DE. Pulse wave analysis. J Hypertens Suppl 1996;14:147-57.
16. 16. Fortier C, Agharazii M. Arterial stiffness gradient. Pulse (Basel) 2016;3:159-66.
17. 17. Tanaka H, Munakata M, Kawano Y, Ohishi M, Shoji T, Sugawara J, et al. Comparison between carotid-femoral and brachial-ankle pulse wave velocity as measures of arterial stiffness. J Hypertens 2009;27:2022-7.
18. 18. Tsuchikura S, Shoji T, Kimoto E, Shinihara K, Hatsuda S, Koyama H, et al. Brachial-ankle pulse wave velocity as an index of central arterial stiffness. J Atheroscler Thromb 2010;17:658-65.
19. 19. McEniery C, Cockcroft J. Does arterial stiffness predict atherosclerotic coronary events? Adv Cardiol 2007;44:160-72.
20. 20. O’Rourke MF, Hashimoto J. Mechanical factors in arterial aging: a clinical perspective. J Am Coll Cardiol 2007;50:1-13.
21. 21. Ikdahl E, Rollefstad S, Hisdal J, Olsen I, Pedersen T, Kvien T, et al. Sustained improvement of arterial stiffness and blood pressure after longterm rosuvastatin treatment in patients with inflammatory joint diseases: results from the RORA-AS study. PLoS One 2016;11:e0153440.
22. 22. Kanaki AI, Sarafidis PA, Georgianos PI, Kanovas K, Tziolas I, Zebekakis P, et al. Effects of low-dose atorvastatin on arterial stiffness and central aortic pressure augmentation in patients with hypertension and hypercholesterolemia. Am J Hypertens 2013;26:608-16.
23. 23. Rosenson RS. Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities. Atherosclerosis 2014;173(1):1-12.
24. 24. Pasceri V, Cheng JS, Willerson JT, Yeh ET, Chang J. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 2001;103:2531-4.
25. 25. Noonan JE, Jenkins AJ, Ma JX, Keech AC, Wang JJ, Lamoureux EL. An update on the molecular actions of fenofibrate andits clinical effects on diabetic retinopathy and other microvascular endpoints in patients with diabetes. Diabetes 2013;62:3968-75.
26. 26. Ryan KE, McCance DR, Powell L, McMahon R, Trimble ER. Fenofibrate and pioglitazone improve endothelial function and reduce arterial stiffness in obese glucose tolerant men. Atherosclerosis 2007;194:123-30.
27. 27. Hiukka A, Westerbacka J, Leinonen ES, Watanabe H, Wiklund O, Hulten LM, et al. Long-term effects of fenofibrate on carotid intima-media thickness and augmentation index in subjects with type 2 diabetes mellitus. J Am Coll Cardiol 2008;52:2190-7.
28. 28. Zhu S, Su G, Meng QH. Inhibitory effects of micronized fenofibrate on carotid atherosclerosis in patients with essential hypertension. Clin Chem 2006;52:2036-42.
29. 29. Wang TD, Chen WJ, Lin JW, Cheng CC, Chen MF, Lee YT. Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles. Atherosclerosis 2003;170:315-23.
30. 30. Yu J, Jin N, Wang G, Zhang F, Mao J, Wang X. PPAR-γ agonist improved arterial stiffness in type 2 diabetes patients with coronary artery disease. Metabolism 2007;56:1396.
31. 31. Wang G, He L, Liu J, Yu J, Feng X, Li F, et al. Coronary flow velocity reserve is improved by PPAR-α agonist fenofibrate in patients with hypertriglyceridemia. Cardiovasc Ther 2013;31:161-7.